{"id":"NCT01730053","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","officialTitle":"A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11-30","primaryCompletion":"2014-04-30","completion":"2014-05-31","firstPosted":"2012-11-21","resultsPosted":"2015-10-28","lastUpdate":"2020-04-07"},"enrollment":305,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["REGN727/SAR236553"]},{"type":"DRUG","name":"Rosuvastatin","otherNames":["Crestor"]},{"type":"DRUG","name":"Ezetimibe","otherNames":["Ezetrol"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rosuvastatin 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe 10 mg + Rosuvastatin 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg","type":"EXPERIMENTAL"},{"label":"Rosuvastatin 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe 10 mg + Rosuvastatin 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg","type":"EXPERIMENTAL"}],"summary":"To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Rosuvastatin 20 mg","deltaMin":-16.3,"sd":4.1},{"arm":"Ezetimibe 10 mg + Rosuvastatin 10 mg","deltaMin":-14.4,"sd":4.4},{"arm":"Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg","deltaMin":-50.6,"sd":4.2},{"arm":"Rosuvastatin 40 mg","deltaMin":-15.9,"sd":7.1},{"arm":"Ezetimibe 10 mg + Rosuvastatin 20 mg","deltaMin":-11,"sd":7.2},{"arm":"Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg","deltaMin":-36.3,"sd":7.1}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG003 vs OG005","p":"=0.0453"},{"comp":"OG004 vs OG005","p":"=0.0136"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":93,"countries":["United States","Australia","Canada","France","Germany","Italy","Mexico","Spain","United Kingdom"]},"refs":{"pmids":["34298554","30183102","27777279","26638010","25269777"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":48},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Pain in extremity","Myalgia","Dizziness"]}}